KIERAN GALLAHUE
CIK 1308428 · Executive Chairman · last filed 2026-05-21
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$22.10M
Companies
7
Total Filings
109
Lifetime Open-Market Net
-$28.19M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NVST | Director | 54,010 | $28.52 | $1.54M | $0 | 8 | 2026-05-21 |
| EW | Director | 82,907 | $93.66 | $7.77M | -$3.32M | 17 | 2026-05-08 |
| Intersect ENT, Inc. (XENT) Delisted | Executive Chairman | 0 | $28.24 | $0 | $101.1K | 12 | 2022-05-16 |
| ARENA PHARMACEUTICALS INC (ARNA) Delisted | Director | 0 | $99.99 | $0 | $0 | 5 | 2022-03-11 |
| CAREFUSION Corp (CFN) Delisted | Chairman and CEO | 740,251 | — | — | -$2.03M | 14 | 2015-03-13 |
| Volcano Corp (VOLC) Delisted | Director | 6,027 | — | — | $0 | 10 | 2013-05-17 |
| RMD | Chief Executive Officer | 56,921 | $224.84 | $12.80M | -$22.95M | 40 | 2011-01-07 |
Recent Filings · Page 4 of 11
109 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-06-07 | Intersect ENT, Inc. (XENT) Delisted | Grant (A) | +1,514 | $0 | EDGAR |
| 2018-05-22 | EW | Mixed | +2,134 | $0 | EDGAR |
| 2017-06-05 | Intersect ENT, Inc. (XENT) Delisted | Grant (A) | +2,546 | $0 | EDGAR |
| 2017-05-15 | EW | Grant (A) | +2,034 | $0 | EDGAR |
| 2017-02-06 | EW | Buy (P) | +3,000 | $270.3K | EDGAR |
| 2017-01-20 | Intersect ENT, Inc. (XENT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-12-01 | EW | Buy (P) | +3,000 | $253.9K | EDGAR |
| 2016-06-06 | Intersect ENT, Inc. (XENT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-05-17 | Intersect ENT, Inc. (XENT) Delisted | Buy (P) | +8,000 | $101.1K | EDGAR |
| 2016-05-17 | EW | Grant (A) | +2,524 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.